RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

RNXT RenovoRx Inc

Market Closed 05-22 16:00:00 EDT

0.8815

-0.0001

-0.01%

盘后0.8700

-0.0115-1.30%

17:38 EDT

High0.9000	Low0.8700	Vol162.56K
Open0.8809	D1 Closing0.8816	Amplitude3.40%
Mkt Cap39.71M	Tradable Cap38.02M	Total Shares45.05M
T/O143.71K	T/O Rate0.38%	Tradable Shares43.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"RNXT","market":"US","secType":"STK","nameCN":"RenovoRx Inc","latestPrice":0.8815,"timestamp":1779480000000,"preClose":0.8816,"halted":0,"volume":162560,"hourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.8815,"latestTime":"17:38 EDT","volume":163,"amount":141.8305,"timestamp":1779485930707,"change":-0.0115,"changeRate":-0.013046,"amplitude":0.013046},"delay":0,"changeRate":-0.00011343012704185572,"floatShares":43131400,"shares":45052700,"eps":-0.331663,"marketStatus":"Market Closed","change":-0.0001,"latestTime":"05-22 16:00:00 EDT","open":0.8809,"high":0.9,"low":0.87,"amount":143710.4429824,"amplitude":0.034029,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.331663,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1779782400000},"marketStatusCode":7,"adr":0,"listingDate":1629950400000,"exchange":"NASDAQ","adjPreClose":0.8816,"preHourTrading":{"tag":"盘前","latestPrice":0.9,"preClose":0.8816,"latestTime":"09:23 EDT","volume":1183,"amount":1077.3359779,"timestamp":1779456202716,"change":0.0184,"changeRate":0.020871,"amplitude":0.012137},"postHourTrading":{"tag":"盘后","latestPrice":0.87,"preClose":0.8815,"latestTime":"17:38 EDT","volume":163,"amount":141.8305,"timestamp":1779485930707,"change":-0.0115,"changeRate":-0.013046,"amplitude":0.013046},"volumeRatio":0.4151085623531864},"requestUrl":"/m/hq/s/RNXT/wiki","defaultTab":"wiki","newsList":[{"id":"2637766323","title":"RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery","url":"https://stock-news.laohu8.com/highlight/detail?id=2637766323","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637766323?lang=en_us&edition=fundamental","pubTime":"2026-05-24 04:50","pubTimestamp":1779569411,"startTime":"0","endTime":"0","summary":"RenovoRx releases investor presentation outlining RenovoCath commercialization ramp and TAMP platform for targeted cancer drug delivery. RenovoRx outlined a commercial ramp for its FDA-cleared RenovoCath drug-delivery catheter, citing 16 active US cancer centers and a pipeline of 32 additional centers in evaluation or onboarding as of May 6, 2026.Projected 2026 revenue of $3-4 million; targeted 36 active commercial cancer centers by year-end.Reported $1.1 million in RenovoCath revenue in 2025; recorded $563,000 in Q1 2026, more than half of the prior-year total.Highlighted a potential peak annual US revenue opportunity of about $400 million for RenovoCath as a standalone device; cited pricing benchmarks of $6,000-$8,500 per unit and 5-6 procedures per patient.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260523:nNDL9k4T41:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637096361","title":"RenovoRx Insider Makes Bold Move With Fresh Share Purchase","url":"https://stock-news.laohu8.com/highlight/detail?id=2637096361","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637096361?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:13","pubTimestamp":1779416013,"startTime":"0","endTime":"0","summary":"New insider activity at RenovoRx ( ($RNXT) ) has taken place on May 21, 2026. RenovoRx’s Chief Financial Officer, Mark Voll, has increased his stak...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/renovorx-insider-makes-bold-move-with-fresh-share-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/renovorx-insider-makes-bold-move-with-fresh-share-purchase-insider-trading-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","BK4139","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637380892","title":"RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690","url":"https://stock-news.laohu8.com/highlight/detail?id=2637380892","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637380892?lang=en_us&edition=fundamental","pubTime":"2026-05-21 19:01","pubTimestamp":1779361267,"startTime":"0","endTime":"0","summary":"RenovoRx CFO Mark Voll reported an open-market purchase of 25,000 common shares at USD 0.79 each.Directly held common shares rose to 142,380 following the transaction.An additional 97,200 common shares were reported as indirectly held through the Voll Family Trust.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on May 21, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260521:nNDL8hWCkV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"RenovoRx CFO Mark Voll buys 25,000 shares valued at $19,690","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636893443","title":"RenovoRx Earnings Call Signals Commercial Inflection","url":"https://stock-news.laohu8.com/highlight/detail?id=2636893443","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636893443?lang=en_us&edition=fundamental","pubTime":"2026-05-20 08:16","pubTimestamp":1779236183,"startTime":"0","endTime":"0","summary":"Renovorx, Inc. (($RNXT)) has held its Q1 earnings call. Read on for the main highlights of the call. RenovoRx’s latest earnings call struck an upbe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-signals-commercial-inflection?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/renovorx-earnings-call-signals-commercial-inflection?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636856203","title":"RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th","url":"https://stock-news.laohu8.com/highlight/detail?id=2636856203","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2636856203?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:30","pubTimestamp":1779193800,"startTime":"0","endTime":"0","summary":"MOUNTAIN VIEW, Calif., May  19, 2026  (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT), a life sciences company developing innovative targeted oncology therapies and com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/19/3297484/0/en/RenovoRx-to-Present-at-the-Alliance-Global-Partners-Virtual-Annual-Healthcare-Company-Showcase-on-May-20th.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","RNXT","LABU","LU0029874061.USD","XBI","BK4588","LU0128526141.USD","BK4539","BK4581","HCSG","BK4139","BK4585","BK4137"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635203245","title":"Analysts Offer Insights on Healthcare Companies: Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) and RenovoRx (RNXT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635203245","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635203245?lang=en_us&edition=fundamental","pubTime":"2026-05-16 03:30","pubTimestamp":1778873420,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Tenaya Therapeutics (TNYA), Lineage Therap (LCTX) an...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-lineage-therap-lctx-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-tenaya-therapeutics-tnya-lineage-therap-lctx-and-renovorx-rnxt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","XBI","LU0029874061.USD","BK4539","LCTX","BK4139","RNXT","BK4588","LU0128526141.USD","TNYA","LABU","BK4137","BK4585","XLV","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635865520","title":"RenovoRx (RNXT) Gets a Buy from H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2635865520","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635865520?lang=en_us&edition=fundamental","pubTime":"2026-05-15 18:56","pubTimestamp":1778842619,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on RenovoRx, with a price target of $3.00. The ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/renovorx-rnxt-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/renovorx-rnxt-gets-a-buy-from-h-c-wainwright-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4539","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721411","title":"RenovoRx Inc reports results for the quarter ended March 31 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721411","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721411?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:48","pubTimestamp":1778795310,"startTime":"0","endTime":"0","summary":"RenovoRx Inc reports results for the quarter ended March 31 - Earnings SummaryRenovoRx Inc RNXT.OQ reported a quarterly adjusted loss of 8 cents per share for the quarter ended March 31, identical to ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL8N41R2N4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635218647","title":"RenovoRx reports Q1 adjusted EPS (8c), consensus (8c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2635218647","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635218647?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:08","pubTimestamp":1778792938,"startTime":"0","endTime":"0","summary":"Reports Q1 revenue $563,000, consensus $463,250. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial ne...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-reports-q1-adjusted-eps-8c-consensus-8c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-reports-q1-adjusted-eps-8c-consensus-8c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635721836","title":"RenovoRx sees FY26 revenue $3M-$4M, consensus $3.24M","url":"https://stock-news.laohu8.com/highlight/detail?id=2635721836","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635721836?lang=en_us&edition=fundamental","pubTime":"2026-05-15 05:02","pubTimestamp":1778792556,"startTime":"0","endTime":"0","summary":"The company believes its current cash resources are sufficient to fund operations into at least the second half of 2027. Published first on TheFly ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/renovorx-sees-fy26-revenue-3m-4m-consensus-3-24m-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/renovorx-sees-fy26-revenue-3m-4m-consensus-3-24m-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["RNXT","MMM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635072512","title":"RenovoRx Q1 net loss widens 45% to $3.52 million; revenue rises 186% to $563,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635072512","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635072512?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:23","pubTimestamp":1778790206,"startTime":"0","endTime":"0","summary":"RenovoRx posted a net loss of USD 3.52 million for the quarter ended March 31, 2026, widening 45% from a year earlier.Revenue climbed to USD 563,000, up 186%, as RenovoCath sales accelerated; gross profit rose to USD 479,000.Operating loss widened to USD 3.47 million, while selling, general and administrative expense increased to USD 2.72 million, up 73%.Cash and cash equivalents totaled USD 12.4 million at March 31, following a USD 10 million private placement that included common stock, pre-funded warrants, and revenue milestone warrants.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nNDLbyPmfH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635259857","title":"RenovoRx Q1 revenue rises as number of active cancer centers increase","url":"https://stock-news.laohu8.com/highlight/detail?id=2635259857","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635259857?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:20","pubTimestamp":1778790052,"startTime":"0","endTime":"0","summary":"RenovoRx Q1 revenue rises as number of active cancer centers increaseOverviewUS oncology device maker's Q1 2026 revenue rose 186% yr/yr on expanding cancer center adoptionNet loss widened to $3.5 mln ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nL1N41R19X:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4539","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635258667","title":"RenovoRx Q1 Adj. EPS $(0.08), Inline, Sales $563.000K Beat $463.250K Estimate.","url":"https://stock-news.laohu8.com/highlight/detail?id=2635258667","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635258667?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:12","pubTimestamp":1778789550,"startTime":"0","endTime":"0","summary":"RenovoRx (NASDAQ:RNXT) reported quarterly losses of $(0.08) per share which met the analyst consensus estimate. This is a 14.29 percent decrease over losses of $(0.07) per share from the same period last year.  The","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/05/52580426/renovorx-q1-adj-eps-0-08-inline-sales-563-000k-beat-463-250k-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635723895","title":"RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-Over-Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635723895","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635723895?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789104,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nTUA4JDYKT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635726557","title":"RenovoRx Q1 Revenue $563,000","url":"https://stock-news.laohu8.com/highlight/detail?id=2635726557","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635726557?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789103,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX760B18:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","RNXT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635581726","title":"RenovoRx Q1 Adjusted EPS USD -0.08 VS. Ibes Estimate USD -0.08","url":"https://stock-news.laohu8.com/highlight/detail?id=2635581726","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635581726?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789103,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX760B18:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242725","title":"RENOVORX REITERATES FULL YEAR 2026 REVENUE GUIDANCE OF $3 MLN - $4 MLN\\n","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242725","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242725?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789103,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260514:nPLX760B18:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635981723","title":"Press Release: RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter","url":"https://stock-news.laohu8.com/highlight/detail?id=2635981723","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635981723?lang=en_us&edition=fundamental","pubTime":"2026-05-15 04:05","pubTimestamp":1778789100,"startTime":"0","endTime":"0","summary":"Q1 2026 Revenue of $563,000 Totals Over 50% of Full Year 2025 Total Revenue. Active Commercial Cancer Center Customers Expand to 16 with Growing Sales Pipeline, Accelerating Adoption of the TAMP Therapy Platform Enabled by the RenovoCath Device. Phase III TIGeR-PaC Trial Advances Toward Completion with Full Enrollment Expected in June 2026. Ended First Quarter with $12.4 million in cash, Sufficient to Fund Operations into at Least the Second Half of 2027. \"Looking ahead, we remain focused on executing against both our near-term commercial priorities and our long-term clinical objectives,\" added Mr. Bagai. \"We expect continued revenue growth throughout 2026, supported by ongoing cancer center activations and continued transition of Phase III TIGeR-PaC trial sites into commercial centers after full enrollment is complete. At the same time, TIGeR-PaC remains on track for complete enrollment in June 2026, reinforcing the strength of our dual-track strategy. With a strengthened balance shee","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"Press Release: RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635242707","title":"RenovoRx Inc  expected to post a loss of 8 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2635242707","media":"Reuters","labels":["preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635242707?lang=en_us&edition=fundamental","pubTime":"2026-05-13 04:02","pubTimestamp":1778616126,"startTime":"0","endTime":"0","summary":"RenovoRx Inc  expected to post a loss of8cents a share - Earnings Preview RenovoRx Inc RNXT.OQ RNXT.O is expected to  show a rise in quarterly revenue when it reports  results on May 14 for the period","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nL8N41P30B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RNXT","BK4139","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633950468","title":"RenovoRx forecasts 2026 revenue of $3 million-$4 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2633950468","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633950468?lang=en_us&edition=fundamental","pubTime":"2026-05-05 02:36","pubTimestamp":1777919790,"startTime":"0","endTime":"0","summary":"RenovoRx forecast 2026 revenue of $3-4 million as it scales commercialization of FDA-cleared RenovoCath.Outlook follows $1.1 million in 2025 RenovoCath revenue, first full year of commercialization.Commercial traction cited as of Feb. 27, 2026: 12 U.S. cancer centers using RenovoCath repeatedly; 21 additional centers engaged in evaluation or activation.Targeting 36 active commercial sites by year-end; more than 700 RenovoCath procedures completed since FDA clearance in 2014.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief on May 04, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260504:nNDL5WZzys:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","RNXT","BK4539"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.renovorx.com;renovorx.com","stockEarnings":[{"period":"1week","weight":0.075},{"period":"1month","weight":-0.0704},{"period":"3month","weight":-0.0343},{"period":"6month","weight":0.1078},{"period":"1year","weight":-0.2833},{"period":"ytd","weight":0.0493}],"compareEarnings":[{"period":"1week","weight":0.0088},{"period":"1month","weight":0.0484},{"period":"3month","weight":0.0815},{"period":"6month","weight":0.1314},{"period":"1year","weight":0.2788},{"period":"ytd","weight":0.0934}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.049533},{"month":2,"riseRate":0.6,"avgChangeRate":0.102207},{"month":3,"riseRate":0.2,"avgChangeRate":-0.093103},{"month":4,"riseRate":0,"avgChangeRate":-0.163527},{"month":5,"riseRate":0.6,"avgChangeRate":0.044394},{"month":6,"riseRate":0.5,"avgChangeRate":0.03467},{"month":7,"riseRate":0.25,"avgChangeRate":-0.034228},{"month":8,"riseRate":0.25,"avgChangeRate":-0.119414},{"month":9,"riseRate":0.4,"avgChangeRate":-0.050074},{"month":10,"riseRate":0,"avgChangeRate":-0.120676},{"month":11,"riseRate":0.6,"avgChangeRate":0.028303},{"month":12,"riseRate":0.6,"avgChangeRate":0.479671}],"exchange":"NASDAQ","name":"RenovoRx Inc","nameEN":"RenovoRx Inc"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"RenovoRx Inc,RNXT,RenovoRx Inc股票,RenovoRx Inc股票老虎,RenovoRx Inc股票老虎国际,RenovoRx Inc行情,RenovoRx Inc股票行情,RenovoRx Inc股价,RenovoRx Inc股市,RenovoRx Inc股票价格,RenovoRx Inc股票交易,RenovoRx Inc股票购买,RenovoRx Inc股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"RenovoRx Inc(RNXT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest RenovoRx Inc(RNXT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}